Protagonist Therapeutics (PTGX) Operating Expenses (2015 - 2026)

Protagonist Therapeutics has disclosed Operating Expenses across 12 years of filings, most recently posting $60.0 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $60.0 million, up 26.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $216.5 million (up 19.91% YoY), and the FY2025 annual result was $204.1 million, up 12.42% from the prior year.
• Operating Expenses came in at $60.0 million for Q1 2026 at Protagonist Therapeutics, up from $57.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $60.0 million in Q1 2026 to a low of $32.3 million in Q3 2022.
• The 5-year median for Operating Expenses is $43.9 million (2024), against an average of $44.6 million.
• Peak annual rise in Operating Expenses reached 55.02% in 2022, while the deepest fall reached 26.94% in 2022.
• Protagonist Therapeutics' Operating Expenses stood at $36.5 million in 2022, then increased by 1.19% to $37.0 million in 2023, then increased by 18.69% to $43.9 million in 2024, then soared by 31.77% to $57.8 million in 2025, then climbed by 3.85% to $60.0 million in 2026.
• The last three Operating Expenses figures came in at $60.0 million (Q1 2026), $57.8 million (Q4 2025), and $51.1 million (Q3 2025), per Business Quant data.